Treatment of neuroblastoma with metaiodobenzylguanidine: results and side effects
Journal Article
·
· Med. Pediatr. Oncol.; (United States)
Between April 1984 and December 1985 we treated ten children suffering from neuroblastoma in a total of 25 metaiodobenzylguanidine (MIBG) courses. Five had had a relapse of neuroblastoma stage III or IV, three had never achieved a remission in spite of intensive chemotherapy, and two were treated with an unstable remission. The children were each administered from 1 to 5 courses with a dosage per course of between 1295 and 9065 MBq. The sum of the single doses during the whole course of therapy ranged between 3145 and 21,904 MBq per child. Five of five children suffering from bone pain and fever became free of complaints during the first three treatment days. Six of eight children with manifest tumor at onset of therapy responded well to the treatment: response extended from transitory decrease in elevated catecholamine levels in serum and urine to complete disappearance of large abdominal tumor masses. We also observed a decrease in bone marrow involvement and a stabilization of osteolytic lesions. Seven of these eight children died in spite of a good response from 55 to 350 days after the first MIBG treatment course. The only side effect we witnessed was a reversible bone marrow depression. In three children we combined the MIBG therapy with bone marrow transplantation.
- Research Organization:
- University Hospital, Tuebingen, Germany, F.R.
- OSTI ID:
- 5625496
- Journal Information:
- Med. Pediatr. Oncol.; (United States), Journal Name: Med. Pediatr. Oncol.; (United States) Vol. 15:4; ISSN MPOND
- Country of Publication:
- United States
- Language:
- English
Similar Records
Clinical experiences in the treatment of neuroblastoma with sup 131 I-metaiodobenzylguanidine
Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial
Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine
Journal Article
·
Tue Dec 31 23:00:00 EST 1985
· Pediatric Hematology and Oncology; (USA)
·
OSTI ID:6322042
Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial
Journal Article
·
Mon Dec 31 23:00:00 EST 1990
· Medical and Pediatric Oncology; (United States)
·
OSTI ID:5474112
Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine
Journal Article
·
Wed Dec 31 23:00:00 EST 1986
· Med. Pediatr. Oncol.; (United States)
·
OSTI ID:5721669
Related Subjects
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
560151 -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ABDOMEN
AGE GROUPS
AMINES
ANIMAL TISSUES
AROMATICS
BODY
BODY AREAS
BONE MARROW
CATECHOLAMINES
CHILDREN
DISEASES
DRUGS
HEMATOPOIETIC SYSTEM
HYDROXY COMPOUNDS
LABELLED COMPOUNDS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PAIN
PHENOLS
POLYPHENOLS
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
SIDE EFFECTS
SYMPTOMS
THERAPEUTIC USES
THERAPY
TISSUES
USES
560151 -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ABDOMEN
AGE GROUPS
AMINES
ANIMAL TISSUES
AROMATICS
BODY
BODY AREAS
BONE MARROW
CATECHOLAMINES
CHILDREN
DISEASES
DRUGS
HEMATOPOIETIC SYSTEM
HYDROXY COMPOUNDS
LABELLED COMPOUNDS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PAIN
PHENOLS
POLYPHENOLS
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
SIDE EFFECTS
SYMPTOMS
THERAPEUTIC USES
THERAPY
TISSUES
USES